Tumor markers as prognostic factors in treated non-small cell lung cancer

被引：0
作者：
Trapé, J
Buxo, J
De Olaguer, JP
Vidal, C
机构：
[1] Hosp San Juan Dios, Serv Anal Clin, Althaia Xarxa Assistencial de Manresa, Barcelona 08243, Spain
[2] Hosp San Juan Dios, Seccio Oncol, Althaia Xarxa Assistencial de Manresa, Barcelona 08243, Spain
[3] Hosp San Juan Dios, Serv Epidemiol, Althaia Xarxa Assistencial de Manresa, Barcelona 08243, Spain
来源：
ANTICANCER RESEARCH | 2003年 / 23卷 / 5B期
关键词：
CYFRA; 21-1; CEA; CA; 125; lung cancer; treatment with chemotherapy; prognostic factor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The usefulness of tumor markers in non-small cell lung carcinoma (NSCLC) is not well defined. The aim of this study was to determine the predictive value for response to treatment and prognosis of pretreatment concentrations of tumor markers. The pretreatment levels of CEA, CA125 and CYFRA21-1 were determined by electrochemoluminiscence in 48 patients with advanced stage (IIIA-IV) NSCLC treated with platin-based chemotherapy. The sensitivity for CYFRA21-1, CA125 and CEA was 66.7%, 45.8% and 47.3%, respectively. The predictive factors for non-response to treatment were CA125>35 KU/L (OR=5.36; p=0.017) and presence of metastasis (OR=6.92, p=0.007). The prognostic factors for survival were Performance Status>1 (HR=4.22; p=0.0002), presence of metastasis (HR = 3.1; p = 0.0028) and CA125>35 KU/L (HR=2.33,p=0.02). In conclusion, CA125 is a predictive factor for response to treatment and a prognostic factor for survival in patients with NSCLC treated with chemotherapy.
引用
收藏
页码：4277 / 4281
页数：5
相关论文
共 24 条
[1]  
Brechot JM, 1997, EUR J CANCER, V33, P385, DOI 10.1016/S0959-8049(96)00498-4
[2]   Prognostic value of histology in patients with non-small cell lung cancer [J].
Charloux, A ;
Hedelin, G ;
Dietemann, A ;
Ifoundza, T ;
Roeslin, N ;
Pauli, G ;
Quoix, E .
LUNG CANCER, 1997, 17 (01) :123-134
[3]  
DIEZ M, 1994, CANCER-AM CANCER SOC, V73, P1368, DOI 10.1002/1097-0142(19940301)73:5<1368::AID-CNCR2820730510>3.0.CO
[4]  
2-O
[5]  
DIEZ M, 1991, CANCER, V67, P150, DOI 10.1002/1097-0142(19910101)67:1<150::AID-CNCR2820670126>3.0.CO
[6]  
2-D
[7]   Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer [J].
Diez, M ;
Torres, A ;
Maestro, ML ;
Ortega, MD ;
Gomez, A ;
Pollan, M ;
Lopez, JA ;
Picardo, A ;
Hernando, F ;
Balibrea, JL .
BRITISH JOURNAL OF CANCER, 1996, 73 (10) :1248-1254
[8]  
Ebert W, 1999, ANTICANCER RES, V19, P2669
[9]   Survival predictors in advanced non-small cell lung cancer [J].
Hespanhol, V ;
Queiroga, H ;
Magalhaes, A ;
Santos, AR ;
Coelho, M ;
Marques, A .
LUNG CANCER, 1995, 13 (03) :253-267
[10]  
KIMURA Y, 1994, EUR J CLIN CHEM CLIN, V32, P189
123